This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Lymphoma	MAP kinase kinase kinase 14 (MAP3K14; NIK); baculoviral IAP repeat-containing 3 (BIRC3; cIAP2); mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1)	A study in cell culture and in patient tissue suggests that inhibiting NIK could help treat MALT lymphoma. In tumor samples from MALT lymphoma patients, cAIP2-MALT1-positive tumors contained higher levels of an NIK cleavage fragment than cAIP2-MALT1-negative tumors. In cAIP2-MALT1-expressing lymphoma cells, small interfering RNA-mediated depletion of NIK led to greater sensitivity to dexamethasone than that seen using control siRNA. Next steps include identifying small molecule NIK inhibitors and developing an animal model of cIAP2-MALT1-induced lymphoma. SciBX 4(7); doi:10.1038/scibx.2011.191 Published online Feb. 17, 2011	Unpatented; licensing status not applicable	Rosebeck, S. <i>et al. Science</i>; published online Jan. 28, 2011; doi:10.1126/science.1198946 Contact: Linda M. McAllister-Lucas, University of Michigan, Ann Arbor, Mich. e-mail: lindaluc@umich.edu Contact: Peter C. Lucas, same affiliation as above e-mail: plucas@umich.edu